drugset / Trial / NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the blood and bone marrow in which the bone marrow makes a large number of abnormal blood cells) and advanced solid tumors and metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2024-12-30
- Primary completion
- 2028-01-19
- Completion
- 2028-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-54179060 | Unknown | — | Oral |
| Subject | JNJ-64264681 | Small molecule | — | Oral |
| Subject | JNJ-70218902 | Other / unclassified | — | Oral |
| Subject | JNJ-74856665 | Unknown | — | Oral |
| Subject | JNJ-80948543 | Unknown | — | Subcutaneous |
| Subject | JNJ-87801493 | Unknown | — | Subcutaneous |
| Subject | ONAMETOSTAT | Small molecule | — | Oral |
| Subject | REZETAMIG | Monoclonal antibody | — | Subcutaneous |
| Subject | SAFIMALTIB | Small molecule | — | Oral |